126 related articles for article (PubMed ID: 27515347)
1. Use of Clays as Nanocarriers of First-Line Tuberculostatic Drugs.
Carazo E; Borrego-Sanchez A; Aguzzi C; Cerezo P; Viseras C
Curr Drug Deliv; 2017; 14(7):902-903. PubMed ID: 27515347
[No Abstract] [Full Text] [Related]
2. Nanocarriers for respiratory diseases treatment: recent advances and current challenges.
Trapani A; Gioia SD; Castellani S; Carbone A; Cavallaro G; Trapani G; Conese M
Curr Top Med Chem; 2014; 14(9):1133-47. PubMed ID: 24678708
[TBL] [Abstract][Full Text] [Related]
3. [Action in vitro of associations of tuberculostatic drugs on strains of mycobacteria with multiple drug resistance].
Timośca S; Coman G; Petreanu V; Georgescu M; Balteanu E
Rev Med Chir Soc Med Nat Iasi; 1975; 79(1):49-53. PubMed ID: 806949
[No Abstract] [Full Text] [Related]
4. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
Sharma A; Sharma S; Khuller GK
J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
[TBL] [Abstract][Full Text] [Related]
5. [Studies on pyrazine derivatives. XXII. Synthesis and tuberculostatic activity of the products of reactions of pyrazinyl-1,3,4-oxadiazol-2-thione with amines].
Pancechowska-Ksepko D; Foks H; Janowiec M; Zwolska-Kwiek Z
Acta Pol Pharm; 1988; 45(3):193-200. PubMed ID: 3149138
[No Abstract] [Full Text] [Related]
6. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis.
Schön T; Juréen P; Chryssanthou E; Giske CG; Sturegård E; Kahlmeter G; Hoffner S; Angeby KA
Int J Tuberc Lung Dis; 2011 Apr; 15(4):502-9. PubMed ID: 21396210
[TBL] [Abstract][Full Text] [Related]
7. Tuberculosis drug resistance: summary report for 2003.
Can Commun Dis Rep; 2004 May; 30(10):93-5. PubMed ID: 15174496
[No Abstract] [Full Text] [Related]
8. [Primary resistance of Mycobacterium tuberculosis].
Barranquero Arola M; Gorritxo Gil B; Goiriena de Gandarias J
Rev Sanid Hig Publica (Madr); 1984; 58(11-12):1107-15. PubMed ID: 6443589
[No Abstract] [Full Text] [Related]
9. Isoniazid activity is terminated by bacterial persistence.
Mitchison DA; Jindani A; Davies GR; Sirgel F
J Infect Dis; 2007 Jun; 195(12):1871-2; author reply 1872-3. PubMed ID: 17492605
[No Abstract] [Full Text] [Related]
10. Varying effects of common tuberculosis drugs on enhancing clofazimine activity in vitro.
Zhang S; Shi W; Feng J; Zhang W; Zhang Y
Emerg Microbes Infect; 2017 Apr; 6(4):e28. PubMed ID: 28442751
[No Abstract] [Full Text] [Related]
11. Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis.
Johnson CM; Pandey R; Sharma S; Khuller GK; Basaraba RJ; Orme IM; Lenaerts AJ
Antimicrob Agents Chemother; 2005 Oct; 49(10):4335-8. PubMed ID: 16189115
[TBL] [Abstract][Full Text] [Related]
12. Persistence, not resistance, is the cause of loss of isoniazid effect.
Wallis RS; Palaci M; Eisenach K
J Infect Dis; 2007 Jun; 195(12):1870-1; author reply 1872-3. PubMed ID: 17492604
[No Abstract] [Full Text] [Related]
13. [Resistance to antitubercular drugs in strains of Mycobacterium tuberculosis isolated in Spain].
Ausina Ruiz V; Lonca Giménez J
Rev Clin Esp; 1999 Mar; 199(3):121-5. PubMed ID: 10230288
[No Abstract] [Full Text] [Related]
14. Drug resistance in tuberculosis.
Ebrahim GJ
J Trop Pediatr; 2007 Jun; 53(3):147-9. PubMed ID: 17526511
[No Abstract] [Full Text] [Related]
15. Multi-Target Antitubercular Drugs.
de Oliveira Viana J; Ishiki HM; Scotti MT; Scotti L
Curr Top Med Chem; 2018; 18(9):750-758. PubMed ID: 29807515
[TBL] [Abstract][Full Text] [Related]
16. [Factors relating to the incidence of drug resistance for anti-tuberculosis drugs during chemotherapy. Influence of background factors, factors regarding the method of treatment and the course of the disease on the emergence of drug resistance].
Yamamoto M; Nakamura H; Inagaki H
Kekkaku; 1970 Oct; 45(10):349-57. PubMed ID: 4991618
[No Abstract] [Full Text] [Related]
17. Minding the gaps in tuberculosis research.
Ekins S; Nuermberger EL; Freundlich JS
Drug Discov Today; 2014 Sep; 19(9):1279-82. PubMed ID: 24993157
[No Abstract] [Full Text] [Related]
18. Current challenges in drug discovery for tuberculosis.
Kumar A; Chettiar S; Parish T
Expert Opin Drug Discov; 2017 Jan; 12(1):1-4. PubMed ID: 27797593
[No Abstract] [Full Text] [Related]
19. [Anti-tuberculosis drugs].
Doi N
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():367-74. PubMed ID: 17455647
[No Abstract] [Full Text] [Related]
20. [Incidence of tuberculostatic-resistant Mycobacterium tuberculosis. Clinical aspects and impact on therapy and clinical course].
Esteban J; Gegúndez MI; García-Corbeira P; Soriano F
Enferm Infecc Microbiol Clin; 1993 Oct; 11(8):415-9. PubMed ID: 8260512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
